Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery

BACKGROUND: The ability to modulate immune-inhibitory pathways using checkpoint blockade antibodies such as αPD-1, αPD-L1, and αCTLA-4 represents a significant breakthrough in cancer therapy in recent years. This has driven interest in identifying small-molecule-immunotherapy combinations to increas...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Molly A., Hughes, Adina M., Walton, Josephine, Coenen-Stass, Anna M. L., Magiera, Lukasz, Mooney, Lorraine, Bell, Sigourney, Staniszewska, Anna D., Sandin, Linda C., Barry, Simon T., Watkins, Amanda, Carnevalli, Larissa S., Hardaker, Elizabeth L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883640/
https://www.ncbi.nlm.nih.gov/pubmed/31779705
http://dx.doi.org/10.1186/s40425-019-0794-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883640/
https://www.ncbi.nlm.nih.gov/pubmed/31779705
http://dx.doi.org/10.1186/s40425-019-0794-7

Ejemplares similares